alexa Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an “Adjuvant”: An Exploratory Study | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an “Adjuvant”: An Exploratory Study

Sherry A. Bradford1* and Akbar Khan2

1AccuTheranostics, 875 Ellicott St – Suite 586, Buffalo, NY, 14203, USA

2Medical Director, Medicor Cancer Centres Inc, 4576 Yonge St, Suite 301, Toronto, ON, M2N 6N4, Canada

*Corresponding Author:
Sherry A. Bradford, PhD
875 Ellicott St – Suite 586
Buffalo, NY, 14203, USA
Tel: 716-688-9600-X100
Fax: 716-688-9601
E-mail: [email protected]

Received date: February 04, 2013; Accepted date: March 11, 2013; Published date: March 13, 2013

Citation: Bradford SA, Khan A (2013) Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an “Adjuvant”: An Exploratory Study. J Cancer Sci Ther 5:120-125. doi: 10.4172/1948-5956.1000197

Copyright: © 2013 Bradford SA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Cancer remains one of the most challenging diseases to treat in this new millennium. In an attempt to increase tumor response rates and decrease patient toxicity to various chemotherapeutic agents, the efficacy of metformin as a chemosensitizer was investigated. Preclinical and clinical evidence supports the use of metformin as a cancer therapeutic particularly in the treatment of cancers known to be associated with hyperinsulinemia, such as those of the breast and colon, as metformin has the ability to lower circulating insulin levels. Moreover, metformin may exhibit direct inhibitory effects on cancer cells by regulating cellular metabolism thereby reducing proliferation and inducing apoptosis. A variety of solid tumor single-cell heterogenates were incubated with chemotherapeutic agents, plus/minus metformin, and analyzed for cell-death. A total of fourteen solid-tumors of various types were studied; ten of the fourteen tumors (71%) exhibited poor or modest sensitivity to the chemo agents tested, but when metformin was combined, a synergistic effect was observed resulting in high sensitivity (high cell kill); one of the fourteen tumors (7%) exhibited a marginal sensitivity to metformin employed as a single agent. Our findings indicate a potential role for metformin in oncology therapeutics as a powerful adjuvant to chemotherapy in a wide range of cancer types.The diversity of the tumor specimens studied further validates the necessity to conduct clinical studies on the efficacy of metformin in the oncology setting. The clinical safety, wellcharacterized pharmacodynamic profile, and low cost of metformin make it an ideal candidate for development as an effective adjuvant anticancer agent. Nonetheless, a randomized controlled clinical trial must be designed to further correlate and validate this preliminary pilot study and to fully appreciate the impact of metformin on cancer recurrence and survival.

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]com

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7